{"entity":{"id":"nct07023731","kind":"trial","name":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","aka":[],"tldr":"A phase 1/2 trial of ARV-806 in advanced solid tumours, run by Arvinas Inc., active and no longer recruiting.","summary":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07023731 by Arvinas Inc., with 76 participants enrolled, started 2025-05-29 and due to reach its primary completion in 2026-11-30. Interventions recorded: ARV-806.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07023731","url":"https://clinicaltrials.gov/study/NCT07023731"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arvinas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07023731","phase":"1/2","setting":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors","sponsor":"Arvinas Inc.","enrolled":76,"outcomes":[]},"route":"/trials/nct07023731/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"arvinas","kind":"company","name":"Arvinas","route":"/companies/arvinas/"}]}}